Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Apnimed, Inc.APMD · Entity 4910 | Chief Financial Officer | July 30, 2026 | August 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Apnimed, Inc.
Report date July 30, 2026 · Filed August 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 · Expires 2036-06-23 | Direct | 0 |
Reported balance
After 2026-08-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-03 · Disposition to issuer · Disposed 333,580 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 22, 2026, and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 · Expires 2036-06-23 | Direct | 333,580 |
Reported balance
After 2026-08-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-03 · Grant · Acquired 333,580 · Balance 333,580 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 22, 2026, and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 31,434 |
Reported balance
After 2036-07-30 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2036-07-30 · Grant · Acquired 31,434 · Balance 31,434 F2: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 22, 2026, and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 0 |
Reported balance
After 2036-08-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2036-08-03 · Disposition to issuer · Disposed 31,434 · Balance 0 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 22, 2026, and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2036-07-29 | Direct | 31,434 |
Reported balance
After 2036-08-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2036-08-03 · Grant · Acquired 31,434 · Balance 31,434 F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 22, 2026, and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock.
F2: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 22, 2026, and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 03, 2036 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | GrantStock Option (Right to Buy) · Derivative | 31,434 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-330510 · ownership.xml · derivative · entry 5 Kelly Michael B · CIK 0002147307 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,434 Underlying: Common Stock · 31,434 shares Expires 2036-07-29 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 22, 2026, and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2036 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 31,434 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-330510 · ownership.xml · derivative · entry 4 Kelly Michael B · CIK 0002147307 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 31,434 shares Expires 2036-07-29 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 22, 2026, and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| July 30, 2036 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | GrantStock Option (Right to Buy) · Derivative | 31,434 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001193125-26-330510 · ownership.xml · derivative · entry 3 Kelly Michael B · CIK 0002147307 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,434 Underlying: Class A Common Stock · 31,434 shares Expires 2036-07-29 F2 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 22, 2026, and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | GrantStock Option (Right to Buy) · Derivative | 333,580 | $0.00 Strike: $8.15 | $0.00 |
DisclosureSEC source: 0001193125-26-330510 · ownership.xml · derivative · entry 2 Kelly Michael B · CIK 0002147307 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,580 Underlying: Common Stock · 333,580 shares Expires 2036-06-23 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 22, 2026, and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
| August 03, 2026 Filed Aug 3, 2026 20:01 UTC | Apnimed, Inc. APMD · Entity 4910 | Disposition to issuerStock Option (Right to Buy) · Derivative | 333,580 | $0.00 Strike: $8.15 | $0.00 |
DisclosureSEC source: 0001193125-26-330510 · ownership.xml · derivative · entry 1 Kelly Michael B · CIK 0002147307 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 333,580 shares Expires 2036-06-23 F1 · kind: Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Class A Common Stock was reclassified into one share of Common Stock. F2 · derivative.exercise_date: 25% of the shares subject to such option vest and become exercisable when the Reporting Person completes twelve months of continuous service after June 22, 2026, and the remainder of the shares vest and become exercisable in substantially equal monthly installments for a period of 36 months thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.